Nyxoah Reports Preliminary Q2 2025 Financial Results

Belgium-based medical tech firm Nyxoah SA announced preliminary, unaudited financial results for Q2 2025. The company, known for its treatment innovations for Obstructive Sleep Apnea (OSA), projects a notable revenue rise to approximately €1.3 million, up 73% from Q2 2024. Operating expenses are expected to reach €20.7 million, marking a 50% increase from the prior year. At the end of June, the company's cash, cash equivalents, and financial assets are estimated at €43 million, with an additional €27.5 million available in a debt facility.

Significant progress includes FDA approval for the Genio® system tailored for adults with moderate to severe OSA. Additionally, Nyxoah plans to wrap up patient enrollment in its ACCCESS clinical trial and relocate its R&D operations to the U.S. and Belgium. Meanwhile, they face legal challenges from Inspire Medical Systems over alleged patent infringements.